Leading manufacturer and supplier of Erlotinib Hydrochloride Intermediates
Erlotinib Hydrochloride CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one CAS 179688-29-0
Please contact: alvin@ruifuchem.com
| Chemical Name |
Erlotinib Hydrochloride |
| Synonyms |
Erlotinib HCl; Tarceva; CP-358774 Hydrochloride; 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline Hydrochloride; N-(3-Ethynylphe nyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine HCl |
| CAS Number |
183319-69-9 |
| CAT Number |
RF-PI2242 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C22H24ClN3O4 |
| Molecular Weight |
429.90 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Crystalline Powder |
| Identification |
A: IR: Conresponding to Reference Spectrum
B: HPLC: Conresponding to Reference RT |
| Solubility |
Very Slightly Soluble in Water, Slightly Soluble in Methanol and Practically Insoluble in Acetonitrile, Acetone, Ethyl Acetate and Hexane |
| Melting Point |
223.0~229.0℃ |
| Loss on Drying |
<0.50% |
| Residue on Ignition |
<0.20% |
| Heavy Metals |
<20ppm |
| Single Impurity |
<0.50% |
| Total Impurities |
<1.00% |
| Residual Solvents |
|
| Pyridine |
<4000ppm |
| Chloroform |
<4000ppm |
| DMF |
<3000ppm |
| Purity / Analysis Method |
>99.0% |
| Assay / Analysis Method |
98.5%~101.0% (Caculated on Anhydrous Basis) |
| Test Standard |
Enterprise Standard |
| Usage |
API |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Erlotinib Hydrochloride (CAS: 183319-69-9) is a small molecule of epidermal growth factor receptor tyrosine kinase reversible inhibitor, is mainly used in the treatment of locally advanced or metastatic non small cell lung cancer and second-line or three line treatment of pancreatic cancer. Erlotinib Hydrochloride was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as Gefitinib, another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide. Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic. Erlotinib Hydrochloride is an HER1/EGFR inhibitor with IC50 of 2 nM. Erlotinib HCl is available as 25-, 100-, and 150-mg tablets fororal administration.